"HLA-A2 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.
Descriptor ID |
D015789
|
MeSH Number(s) |
D12.776.395.550.489.400.020 D12.776.543.550.439.400.020 D23.050.301.500.100.400.020 D23.050.301.500.450.370.020 D23.050.705.552.100.400.020 D23.050.705.552.450.370.374
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HLA-A2 Antigen".
Below are MeSH descriptors whose meaning is more specific than "HLA-A2 Antigen".
This graph shows the total number of publications written about "HLA-A2 Antigen" by people in this website by year, and whether "HLA-A2 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
1996 | 1 | 0 | 1 |
1997 | 0 | 1 | 1 |
1998 | 1 | 1 | 2 |
1999 | 2 | 2 | 4 |
2000 | 1 | 0 | 1 |
2001 | 1 | 0 | 1 |
2002 | 1 | 0 | 1 |
2003 | 0 | 6 | 6 |
2004 | 1 | 2 | 3 |
2005 | 0 | 4 | 4 |
2006 | 0 | 4 | 4 |
2007 | 0 | 5 | 5 |
2008 | 1 | 6 | 7 |
2009 | 1 | 0 | 1 |
2010 | 0 | 4 | 4 |
2011 | 2 | 6 | 8 |
2012 | 3 | 2 | 5 |
2013 | 0 | 1 | 1 |
2015 | 2 | 0 | 2 |
2016 | 3 | 2 | 5 |
2017 | 0 | 2 | 2 |
2018 | 2 | 0 | 2 |
2019 | 1 | 0 | 1 |
2020 | 1 | 1 | 2 |
2021 | 1 | 1 | 2 |
2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "HLA-A2 Antigen" by people in Profiles.
-
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Res. 2023 08 01; 33(4):332-337.
-
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ. Cancer Prev Res (Phila). 2023 06 01; 16(6):333-341.
-
Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia. Cytotherapy. 2021 09; 23(9):793-798.
-
Global analysis of shared T?cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity. 2021 03 09; 54(3):586-602.e8.
-
Preclinical Studies of the Off-Target Reactivity of AFP158-Specific TCR Engineered T Cells. Front Immunol. 2020; 11:607.
-
Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia. Leukemia. 2020 06; 34(6):1626-1636.
-
A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2. Front Immunol. 2018; 9:3153.
-
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design. Clin Immunol. 2018 10; 195:28-35.
-
Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. Clin Cancer Res. 2018 07 15; 24(14):3386-3396.
-
An Isolated TCR a? Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8+ T Cells To Kill and Secrete IFN-? in Response to Lung Adenocarcinoma Cell Lines. J Immunol. 2018 04 15; 200(8):2965-2977.